Table 2.
Comparison of the approved product formulations
| Product | Avastin* | Herceptin** | Remicade** |
|---|---|---|---|
| Aggregation in product-dextrose-plasma mixture | yes | yes | no |
| Active pharmaceutical ingredient (Concentration in mg/mL) | Bevacizumab (25) | Trastuzumab (21) | Infliximab (10) |
| Formulation (mg/mL) | |||
| α,α-trehalose dihydrate | 60 | 20 | |
| sucrose | 50 | ||
| NaH2PO4•H2O | 5.8 | 0.22 | |
| Na2HPO4 | 1.2 | ||
| Na2HPO4•2H2O | 0.61 | ||
| L-histidine HCl | 0.495 | ||
| L-histidine | 0.32 | ||
| polysorbate 20 | 0.4 | 0.09 | |
| polysorbate 80 | 0.05 | ||
| pH | 6.2 | 6.0 | 7.2 |
*
Obtained from the FDA approved label for liquid formulated Avastin.
**
Calculated from the formula information on the FDA approved labels for lyophilized Herceptin and Remicade after reconstitution with the specified volumes of water.